These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 25236396)
1. Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients. Guzmán-Fulgencio M; Berenguer J; Pineda-Tenor D; Jiménez-Sousa MA; García-Álvarez M; Aldámiz-Echevarria T; Carrero A; Diez C; Tejerina F; Vázquez S; Briz V; Resino S Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):385-93. PubMed ID: 25236396 [TBL] [Abstract][Full Text] [Related]
2. TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients. Jiménez-Sousa MA; Rallón N; Berenguer J; Pineda-Tenor D; López JC; Soriano V; Guzmán-Fulgencio M; Cosín J; Retana D; García-Álvarez M; Miralles P; Benito JM; Resino S J Clin Virol; 2015 Apr; 65():62-7. PubMed ID: 25766991 [TBL] [Abstract][Full Text] [Related]
3. Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study. Guzmán-Fulgencio M; Berenguer J; Jiménez-Sousa MA; Pineda-Tenor D; Aldámiz-Echevarria T; García-Broncano P; Carrero A; García-Álvarez M; Tejerina F; Diez C; Vazquez-Morón S; Resino S J Transl Med; 2015 Jun; 13():206. PubMed ID: 26123260 [TBL] [Abstract][Full Text] [Related]
4. CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients. Pineda-Tenor D; Berenguer J; Jiménez-Sousa MA; Guzmán-Fulgencio M; Aldámiz-Echevarria T; Carrero A; García-Álvarez M; Diez C; Tejerina F; Briz V; Resino S J Clin Virol; 2014 Nov; 61(3):423-9. PubMed ID: 25218243 [TBL] [Abstract][Full Text] [Related]
5. HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. Guzmán-Fulgencio M; Berenguer J; Rallón N; Fernández-Rodríguez A; Miralles P; Soriano V; Jiménez-Sousa MA; Cosín J; Medrano J; García-Álvarez M; López JC; Benito JM; Resino S AIDS; 2013 May; 27(8):1231-8. PubMed ID: 23811951 [TBL] [Abstract][Full Text] [Related]
6. Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients. Medrano LM; Rallón N; Berenguer J; Jiménez-Sousa MA; Soriano V; Aldámiz-Echevarria T; Fernández-Rodríguez A; García M; Tejerina F; Martínez I; Benito JM; Resino S J Transl Med; 2016 Sep; 14(1):257. PubMed ID: 27590274 [TBL] [Abstract][Full Text] [Related]
7. European mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients. Guzmán-Fulgencio M; Rallón N; Berenguer J; Fernández-Rodríguez A; Soriano V; Miralles P; Jiménez-Sousa MA; Restrepo C; López JC; García-Álvarez M; Aldámiz T; Benito JM; Resino S HIV Med; 2014 Aug; 15(7):425-30. PubMed ID: 24580757 [TBL] [Abstract][Full Text] [Related]
8. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. Fernández-Rodríguez A; Rallón N; Berenguer J; Jiménez-Sousa MA; Cosín J; Guzmán-Fulgencio M; Restrepo C; Lopez JC; García-Álvarez M; Miralles P; Soriano V; Benito JM; Resino S AIDS; 2013 Jan; 27(2):163-73. PubMed ID: 23135173 [TBL] [Abstract][Full Text] [Related]
9. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA; Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784 [TBL] [Abstract][Full Text] [Related]
10. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection. Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734 [TBL] [Abstract][Full Text] [Related]
11. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817 [TBL] [Abstract][Full Text] [Related]
12. IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection. Jiménez-Sousa MA; Berenguer J; Rallón N; Pineda-Tenor D; Aldamiz-Echevarria T; Soriano V; García-Álvarez M; Vazquez-Morón S; Restrepo C; Carrero A; Benito JM; Resino S Liver Int; 2016 Sep; 36(9):1258-66. PubMed ID: 26836972 [TBL] [Abstract][Full Text] [Related]
13. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129 [TBL] [Abstract][Full Text] [Related]
14. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356 [TBL] [Abstract][Full Text] [Related]
15. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin. Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106 [TBL] [Abstract][Full Text] [Related]
16. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy. Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136 [TBL] [Abstract][Full Text] [Related]
17. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157 [TBL] [Abstract][Full Text] [Related]
18. PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy. Fernández-Rodríguez A; Berenguer J; Rallón N; Jiménez-Sousa MA; López JC; Soriano V; García-Álvarez M; Cosín J; Martínez P; Guzmán-Fulgencio M; Miralles P; Miguel Benito J; Resino S J Acquir Immune Defic Syndr; 2014 Oct; 67(2):113-9. PubMed ID: 25072612 [TBL] [Abstract][Full Text] [Related]
19. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435 [TBL] [Abstract][Full Text] [Related]
20. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Pineda JA; Caruz A; Rivero A; Neukam K; Salas I; Camacho A; Palomares JC; Mira JA; Martínez A; Roldán C; de la Torre J; Macías J Clin Infect Dis; 2010 Oct; 51(7):788-95. PubMed ID: 20804372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]